John W. Moroney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John W. Moroney has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Aung Naing
§Department of Gynecology, The University of Texas M. D. Anderson Cancer Center
1 shared publicationChristine Rojas
Wright State University, Department of Obstetrics and Gynecology, 128 Apple Street, Suite 3800 Weber CHE, Dayton, OH 45409, USA
1 shared publicationDavid S. Hong
¶Department of Investigational Cancer Therapeutics (A Phase I Program), The University of Texas M.D. Anderson Cancer Center
1 shared publication- Diane C. Bodurka
The University of Texas MD Anderson Cancer Center
1 shared publication Filip Janku
¶Department of Investigational Cancer Therapeutics (A Phase I Program), The University of Texas M.D. Anderson Cancer Center
1 shared publicationMatthew P. Schlumbrecht
§Department of Gynecology, The University of Texas M. D. Anderson Cancer Center
1 shared publication
Latest Publications
- Open Access
- 3 April 2013
- Published by Elsevier in Gynecologic Oncology Case Reports
- Vol. 5, 40-2
Robotic surgical staging for cervical cancer diagnosed during pregnancy: Immediate versus delayed definitive treatment.
- 3 April 2013
- Published by Elsevier in Gynecologic Oncology Case Reports
- Vol. 5, 40-2
Open AccessRobotic surgical staging for cervical cancer diagnosed during pregnancy: Immediate versus delayed definitive treatment.
- 31 October 2011
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (21) , 6840-6846
A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies
Purpose: Liposomal doxorubicin (D) and bevacizumab (A) are active single agents in gynecologic and breast malignancies which share a resistance mechanism: upregulation of hypoxia inducible factor (HIF-1α). We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates. Patients and Methods: Cycle length was 21 days, with IV D, A, and T on day 1; T on days 8 and 15 (3+3 dose-escalation design with expansion cohorts). Mutational assays for PIK3CA, BRAF, KRAS, and immunhistochemistry for PTEN loss were conducted. Results: This article details 74 patients with gynecologic and breast malignancies who received at least one dose of drug on study. Median patient age: 52 (27–79); prior regimens: 4 (1–11). Responses: 1 (1.4%) complete response (CR), 14 (18.9%) partial responses (PR), and 13 (17.6%) with stable disease (SD) ≥ 6 months (total = 37.9%). The most common grade 1 toxicities were fatigue (27%) and anemia (20.2%). Notable grade 3/4 toxicities: thrombocytopenia (9.5%), mucositis (6.7%), and bowel perforation (2.7%). PIK3CA mutations or PTEN loss were identified in 25 of 59 (42.3%) of tested patients. Among these, nine (36%) achieved CR/PR and four (16%) had SD ≥ 6 months (CR+PR+SD ≥ 6 months = 52%). Conclusions: DAT is well tolerated with manageable side effects. Responses observed warrant further evaluation. Mutational analyses were notable for a high percentage of responders with phosphoinositide-3-kinase pathway aberrations. Clin Cancer Res; 17(21); 6840–6. ©2011 AACR.
- 31 October 2011
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (21) , 6840-6846
A Phase I Trial of Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Patients with Advanced Gynecologic and Breast Malignancies
Purpose: Liposomal doxorubicin (D) and bevacizumab (A) are active single agents in gynecologic and breast malignancies which share a resistance mechanism: upregulation of hypoxia inducible factor (HIF-1α). We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates. Patients and Methods: Cycle length was 21 days, with IV D, A, and T on day 1; T on days 8 and 15 (3+3 dose-escalation design with expansion cohorts). Mutational assays for PIK3CA, BRAF, KRAS, and immunhistochemistry for PTEN loss were conducted. Results: This article details 74 patients with gynecologic and breast malignancies who received at least one dose of drug on study. Median patient age: 52 (27–79); prior regimens: 4 (1–11). Responses: 1 (1.4%) complete response (CR), 14 (18.9%) partial responses (PR), and 13 (17.6%) with stable disease (SD) ≥ 6 months (total = 37.9%). The most common grade 1 toxicities were fatigue (27%) and anemia (20.2%). Notable grade 3/4 toxicities: thrombocytopenia (9.5%), mucositis (6.7%), and bowel perforation (2.7%). PIK3CA mutations or PTEN loss were identified in 25 of 59 (42.3%) of tested patients. Among these, nine (36%) achieved CR/PR and four (16%) had SD ≥ 6 months (CR+PR+SD ≥ 6 months = 52%). Conclusions: DAT is well tolerated with manageable side effects. Responses observed warrant further evaluation. Mutational analyses were notable for a high percentage of responders with phosphoinositide-3-kinase pathway aberrations. Clin Cancer Res; 17(21); 6840–6. ©2011 AACR.